Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

September 29, 2024

Study Completion Date

November 27, 2024

Conditions

MRI

Interventions

DRUG

HRS-9231or matching placebo

HRS-9231 injection or matching placebo will be administered through IV injection.

Trial Locations (1)

Linear Clinical research, Perth

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY

NCT06519981 - Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians | Biotech Hunter | Biotech Hunter